We are live on ! Find out more
TRVI icon

Trevi Therapeutics

164 hedge funds and large institutions have $1.18B invested in Trevi Therapeutics in 2025 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 65 increasing their positions, 42 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more capital invested

Capital invested by funds: $627M → $1.18B (+$556M)

55% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 42

52% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 23

8.45% more ownership

Funds ownership: 97.75%106.2% (+8.4%)

7% more funds holding

Funds holding: 153164 (+11)

14% less funds holding in top 10

Funds holding in top 10: 76 (-1)

48% less call options, than puts

Call options by funds: $8.43M | Put options by funds: $16.3M

Holders
164
Holders Change
+11
Holders Change %
+7.19%
% of All Funds
2.15%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.08%
New
35
Increased
65
Reduced
42
Closed
23
Calls
$8.43M
Puts
$16.3M
Net Calls
-$7.85M
Net Calls Change
-$11.9M

TRVI Hedge Fund Activity: Q3 2025 in Review

164 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q3 2025, worth a combined $1.18B — up 89% from $627M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new TRVI positions and 23 closed out — a net gain of 12 holders — while 65 added to existing stakes and 42 trimmed.

The largest buyer was Viking Global Investors, adding an estimated $26.9M. The largest seller was Woodline Partners, cutting an estimated $29.6M.

  • 164 institutional investors held Trevi Therapeutics (TRVI) as of Q3 2025, up from 153 in Q2 2025.
  • Funds reported $1.18B of Trevi Therapeutics stock for Q3 2025, up 89% quarter-over-quarter.
  • 35 funds opened new Trevi Therapeutics positions in Q3 2025 and 23 closed out, a net change of +12 holders.
  • The largest Trevi Therapeutics buyer in Q3 2025 was Viking Global Investors, an estimated $26.9M added.
  • The largest Trevi Therapeutics seller in Q3 2025 was Woodline Partners, an estimated $29.6M sold.

Based on aggregated 13F filings for Q3 2025.